Fatal status epilepticus associated with olanzapine therapy

Annals of Pharmacotherapy

Volumn 33, Issue 7-8, 1999, Pages 787-789

  Wyderski, Richard J ^a,c   Grant Starrett, W ^d   Abou Saif, Alaa ^a,b  

^a WRIGHT STATE UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c MIAMI VALLEY HOSPITAL   (United States)

^d NONE

Author keywords

Olanzapine; Status epilepticus

Indexed keywords

CLOZAPINE; OLANZAPINE;

ADULT; ARTICLE; CASE REPORT; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE RESPONSE; DRUG MARKETING; DRUG MECHANISM; DRUG SURVEILLANCE PROGRAM; EPILEPTIC STATE; FATALITY; FEMALE; HUMAN; HUMAN TISSUE; MANIC DEPRESSIVE PSYCHOSIS; NEUROLEPTIC MALIGNANT SYNDROME; PRIORITY JOURNAL; RHABDOMYOLYSIS; TONIC CLONIC SEIZURE;

EID: 0345411594     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.18399     Document Type: Article

References (13)

1. Fulton B, Goa KL. Olanzapine: a review of its pharmacologic properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 1997;53:281-98.
2. Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-65.
3. Data on file, Lilly Research Laboratories, Indianapolis, IN.
4. Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry 1996;57(11 suppl):12-25.
5. Drugs for psychotic disorders. Med Lett Drugs Ther 1997;39:33-40.
6. Devinsky O, Pacia SV. Seizures during clozapine therapy. J Clin Psychiatry 1994;55(9 suppl B):153-6.
7. Casey DE. Side effect profiles of the new antipsychotic agents. J Clin Psychiatry 1996;57(11 suppl):40-5.
8. Beasley CM, Tollefson GD, Tran PV, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-23.
9. Ring BJ, Binkley SN, Vandenbranden M, Wrighton SA. In vitro interaction of the antipsychotic olanzapine with human cytochrome P450 CYP2C9, CYP2C19, CYP2D6, and CYP3A. Br J Clin Pharmacol 1996; 41:181-6.
10. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
11. Bithell TC. Acquired coagulation disorders. In: Wintrobe's clinical hematology. 9th ed. Philadelphia: Lea & Febiger, 1993:1473-514.
12. Felcher A, Commichau C, Cao Q, Brown MJ, Torres A, Francis CW. Disseminated intravascular coagulation and status epilepticus. Neurology 1998;51:629-31.
13. Hasan S, Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am J Psychiatry 1998;155:1113-6.